Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Inclusion Criteria: De novo and primary Ph/BCR-ABL1 negative acute lymphoblastic leukemia diagnosed by the bone marrow cytomorphology, immunophenotyping, cytogenetics and molecular biology according to WHO classification Age: 14 -60 years Male or female ECOG Performance Status 0-2 Adequate end organ function as defined by: Total bilirubin ≤ 1.5 x upper limit of normal（ULN）; serum alanine aminotransferase (ALT) and serum aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤5 x ULN if leukemic involvement of the liver is present; Creatinine ≤ 1.5 x ULN; Serum amylase and lipase ≤ 1.5 x ULN; Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related; normal electrolytes: Potassium ≥ LLN; Magnesium ≥ LLN; Phosphorus ≥ LLN; Cardiac color Doppler ultrasound ejection fraction ≥ 45%; Subject has provided written informed consent prior to any screening procedure Exclusion Criteria: Burkitt lymphoma/leukemia Acute Leukemia of Ambiguous Lineage Female patients who are pregnant or breast feeding Uncontrolled active serious infections that could, in the investigator's opinion, potentially interfere with the completion of treatment History of pancreatitis Poorly controlled diabetes, defined as glycosylated hemoglobin (HbA1c) values of >7.5%. Patients with preexisting, well-controlled diabetes are not excluded History of active gastrointestinal bleeding within the last 6 months History of arterial/venous thrombosis within the last 6 months Known HIV seropositivity Any serious psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment